Biogen Inc. (BIIB) Revenue by Segment & Business Profile
Tysabri Product was 16.0% of Biogen Inc.'s revenue across the 10 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BIIBBiogen Inc.Follow BIIB — free
—
Price chart with a free account
- Market cap
- 37.0B
- P/E TTM
- 44.5
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
What the company does
Biogen Inc. is a drug manufacturers - general company in the healthcare sector. In its SEC filings it reports 10 business lines: Tysabri Product (16%), Fumarate (10%), Contract Manufacturing And Other Revenue (8%), Interferon (8%) and others. Trailing twelve-month revenue: $10.0 billion as of 2026-06-30.
Roles we read
from the filings, not the sector label- Biologics / biotech major
Revenue by geography
fiscal year 2025 · company segment note| Region | Revenue | Share | y/y |
|---|---|---|---|
| United States | 5.74B | 58.0% | +8.1% |
| Europe Excluding Germany | 1.88B | 19.1% | -13.3% |
| Germany | 853M | 8.6% | -10.7% |
| Asia | 727M | 7.3% | +16.4% |
| Segment Geographical Groups Of Countries Group Other | 511M | 5.2% | -8.4% |
Biogen Inc. — questions
- What does Biogen Inc. do?
- Biogen Inc. is a drug manufacturers - general company in the healthcare sector. In its SEC filings it reports 10 business lines: Tysabri Product (16%), Fumarate (10%), Contract Manufacturing And Other Revenue (8%), Interferon (8%) and others. Trailing twelve-month revenue: $10.0 billion as of 2026-06-30.
- How does Biogen Inc. make money?
- By the lines it reports in its SEC filings: Tysabri Product 16.0%, Fumarate 10.5%, Contract Manufacturing And Other Revenue 8.5%, Interferon 8.2%, VUMERITY 7.2% of revenue.
Every figure on this page comes from Biogen Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.